New Product Marketing Blurs the Line Between Nicotine Replacement Therapy and Smokeless Tobacco Products
Author(s) -
Ganna Kostygina,
Lucinda J. England,
Pamela M. Ling
Publication year - 2016
Publication title -
american journal of public health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.284
H-Index - 264
eISSN - 1541-0048
pISSN - 0090-0036
DOI - 10.2105/ajph.2016.303057
Subject(s) - nicotine replacement therapy , nicotine , smokeless tobacco , snus , medicine , tobacco product , tobacco harm reduction , business , chewing gum , smoking cessation , tobacco industry , environmental health , tobacco use , food science , population , chemistry , pathology
Tobacco companies have begun to acquire pharmaceutical subsidiaries and recently started to market nicotine replacement therapies, such as Zonnic nicotine gum, in convenience stores. Conversely, tobacco companies are producing tobacco products such as tobacco chewing gum and lozenges that resemble pharmaceutical nicotine replacement products, including a nicotine pouch product that resembles snus pouches. This convergence of nicotine and tobacco product marketing has implications for regulation and tobacco cessation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom